TES-Based Cationic Lipids with Cleavable Groups for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for cationic lipids that can be synthesized efficiently and cheaply without forming toxic by-products, which are effective for the in vivo delivery of nucleic acids while maintaining a favorable toxicity profile and achieving high encapsulation efficiencies.
Innovation Solution
The development of a novel class of cationic lipid compounds synthesized from readily available 'Good' buffers, incorporating cleavable groups such as esters and disulphides to enhance biodegradability and toxicity profile, formulated into lipid nanoparticles for therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cationic lipids are synthesized for in vivo delivery of nucleic acids, then encapsulation efficiency is achieved, but toxic by-products are formed and toxicity profile deteriorates
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by incorporating cleavable groups (esters and disulphides) that change the lipid's parameters under specific physiological conditions. These parameter changes enable the lipids to degrade into non-toxic products after delivering their cargo, resolving the contradiction between achieving encapsulation efficiency and avoiding toxic by-products
Solution Approach 2:
The patent converts the potential harm of stable cationic lipids (which persist as toxic by-products) into a benefit by designing lipids with cleavable groups. The stability needed for encapsulation is maintained initially, then converted to degradability after delivery, turning the harmful persistence into a beneficial controlled degradation process
2Reliability
If cationic lipids are synthesized from complex starting materials to achieve effective delivery, then delivery performance is improved, but manufacturing cost increases and synthesis efficiency decreases
Solution Approach 1:
The patent employs Good's buffers as universal starting materials that serve multiple functions: they provide the cationic head group, the buffering capacity for pH control during synthesis, and the backbone structure. This multi-functionality simplifies the synthesis pathway and improves productivity while maintaining delivery performance
Solution Approach 2:
The patent uses readily available, inexpensive Good's buffers as starting materials instead of complex, expensive specialized reagents. These simple, short-lived intermediates are easily synthesized and discarded after serving their purpose, improving both manufacturing cost efficiency and synthesis productivity
3Object-generated harmful factors
If cationic lipids are designed with enhanced biodegradability through cleavable groups, then toxicity profile is improved, but encapsulation efficiency may deteriorate
Solution Approach 1:
The patent introduces dynamic characteristics to the cationic lipids by incorporating cleavable groups that respond to physiological conditions. The lipids dynamically transition from a stable encapsulation state to a degraded non-toxic state, allowing them to maintain high encapsulation efficiency initially while achieving improved toxicity profile through controlled degradation
Data Source
AI summary
The present invention provides, in part, TES-based lipid compounds of Formula (Ia), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.